Evidence map›Paper›PMID 29374672›Full record

ArticleBMJ open2018

Study protocol for a cluster randomised controlled factorial design trial to assess the effectiveness and feasibility of reactive focal mass drug administration and vector control to reduce malaria transmission in the low endemic setting of Namibia.

Oliver F Medzihradsky, Immo Kleinschmidt, Davis Mumbengegwi, Kathryn W Roberts, Patrick McCreesh, Mi-Suk Kang Dufour, Petrina Uusiku, Stark Katokele, Adam Bennett, Jennifer Smith and 10 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02610400 (Targeted Parasite Elimination in the Human and Mosquito to Reduce Malaria Transmission), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02610400 phase3completednot on this map

Targeted Parasite Elimination in the Human and Mosquito to Reduce Malaria Transmission: A Cluster Randomised Controlled Factorial Design Trial of Reactive Focal Drug Administration (rfMDA) Versus Reactive Case Detection (RACD), With and Without Reactive Vector Control (RAVC), From the Low Endemic Setting of Namibia

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2017Enrolled9,845ConditionsMalariaArmsRACD, RAVC, rfMDA
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. PvMSP8 as a NovelPathogens (Basel, Switzerland) · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 5 countries.

Oliver F MedzihradskyMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California, USA.
Immo KleinschmidtDepartment of Infectious Disease Epidemiology, The London School of Hygiene and Tropical Medicine, London, UK.
Davis MumbengegwiMultidisciplinary Research Centre, University of Namibia, Windhoek, Namibia.
Kathryn W RobertsMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California, USA.
Patrick McCreeshDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Mi-Suk Kang DufourDivision of Prevention Science, University of California San Francisco, San Francisco, California, USA.
Petrina UusikuNational Vector-borne Diseases Control Programme, Ministry of Health and Social Services, Windhoek, Namibia.
Stark KatokeleNational Vector-borne Diseases Control Programme, Ministry of Health and Social Services, Windhoek, Namibia.
Adam BennettMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California, USA.
Jennifer SmithMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California, USA.
Hugh SturrockMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California, USA.
Lisa M PrachMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California, USA.
Henry NtukuMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California, USA.
Munyaradzi TamboFaculty of Health Sciences, School of Pathology, University of Witwatersrand, Johannesburg, South Africa.
Bradley DidierClinton Health Access Initiative, Boston, Massachusetts, USA.
Bryan GreenhouseDivision of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Zaahira GaniNovartis Foundation, Basel, Switzerland.
Ann AertsNovartis Foundation, Basel, Switzerland.
Roly GoslingMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California, USA.
Michelle S HsiangMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California, USA.
University of California, San Francisco · USMinistry of Health and Social Services · NANovartis Foundation · CHUCSF Benioff Children's Hospital · USUniversity of the Witwatersrand · ZAClinton Health Access Initiative · USThe University of Texas Southwestern Medical Center · USUniversity of Namibia · NA

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
Medical Research Council MR/K012126/1NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

introductionTo interrupt malaria transmission, strategies must target the parasite reservoir in both humans and mosquitos. Testing of community members linked to an index case, termed reactive case detection (RACD), is commonly implemented in low transmission areas, though its impact may be limited by the sensitivity of current diagnostics. Indoor residual spraying (IRS) before malaria season is a cornerstone of vector control efforts. Despite their implementation in Namibia, a country approaching elimination, these methods have been met with recent plateaus in transmission reduction. This study evaluates the effectiveness and feasibility of two new targeted strategies, reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC) in Namibia. METHODS AND ANALYSIS: This is an open-label cluster randomised controlled trial with 2×2 factorial design. The interventions include: rfMDA (presumptive treatment with artemether-lumefantrine (AL)) versus RACD (rapid diagnostic testing and treatment using AL) and RAVC (IRS with Acellic 300CS) versus no RAVC. Factorial design also enables comparison of the combined rfMDA+RAVC intervention to RACD. Participants living in 56 enumeration areas will be randomised to one of four arms: rfMDA, rfMDA+RAVC, RACD or RACD+RAVC. These interventions, triggered by index cases detected at health facilities, will be targeted to individuals residing within 500 m of an index. The primary outcome is cumulative incidence of locally acquired malaria detected at health facilities over 1 year. Secondary outcomes include seroprevalence, infection prevalence, intervention coverage, safety, acceptability, adherence, cost and cost-effectiveness. ETHICS AND DISSEMINATION: Findings will be reported on clinicaltrials.gov, in peer-reviewed publications and through stakeholder meetings with MoHSS and community leaders in Namibia. TRIAL REGISTRATION NUMBER: NCT02610400; Pre-results.

Indexed as

InsecticidesMass Drug AdministrationMosquito VectorsAdultAnimalsAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsChildDrug CombinationsEthanolaminesFemaleFluorenesHumansMalariaMaleAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsDrug CombinationsEthanolaminesFluorenesInsecticidesOrganothiophosphorus Compoundspirimiphos methylartemether-lumefantrinecluster randomisationeliminationindoor residual sprayinglow transmissionmalariamass drug administrationNamibiapirimiphos-methylPlasmodium falciparumpresumptive treatmentreactive case detectionvector control

Identifiers

PMID29374672
PMCPMC5829876
OpenAlexW2788929045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.